Physician profile
Haresh Ailani
NPI 1992964837
$5,684.56
in general payments reported to CMS, 2019-2025
26 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $285 · 2021: $409 · 2022: $401 · 2023: $2,388 · 2024: $766 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Travel and Lodging: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.45 |
| Travel and Lodging | $1,449.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,598.47 | 2019-2025 | Lensx, Centurion, Clareon |
| Abbvie INC. | $739.94 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $294.63 | 2019-2024 | Cequa |
| Allergan, INC. | $274.72 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $215.91 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $204.93 | 2019-2025 | Tecnis Simplicity |
| Rxsight INC | $196.30 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $130.06 | 2023-2025 | Xiidra, Miebo, Doctors Allergy Formula |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.34 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $104.07 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $95.59 | 2020-2023 | Sion Surgical Instrument, Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $94.78 | 2021 | |
| Harrow Eye, LLC | $91.95 | 2024-2025 | Vevye, Triesence |
| Oyster Point Pharma, INC. | $86.81 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $70.14 | 2019-2025 | Oxervate |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $64.76 | 2019-2020 | |
| Glaukos Corporation | $47.91 | 2023-2025 | Idosetr |
| Amgen INC. | $44.07 | 2024 | Tepezza |
| Thea Pharma INC. | $40.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $39.81 | 2023 | |
| Biotissue Holdings INC. | $33.11 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $27.10 | 2020 | |
| Pfizer INC. | $20.57 | 2023 | |
| Rayner Intraocular Lenses Limited | $20.34 | 2025 | Omidria |
| Ocular Therapeutix, INC. | $17.99 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.27 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haresh Ailani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.